When the field of cancer care was still in its infancy, a line was drawn down the middle: solid tumors like breast or lung cancer on one side, and blood cancers like leukemia and lymphoma on the other.
For decades, a diagnosis in the latter category was largely a death sentence. But fifty years ago, a high-risk medical gamble in a handful of labs across the United States forever changed the trajectory of oncology.
Thursday, May 28, as the global medical community marks World Blood Cancer Day, that history is colliding with next-generation cellular engineering at the edge of the Phoenix metro area.
